clinical trial · NCT07456046
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
D3 Bio (Wuxi) Co., Ltd·phase1·recruiting·n = 42
KRAS P.G12DD3S-003
brief summary
This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
started
Mar 31, 2026
primary completion
Jan 11, 2028
completion
Jan 11, 2028
last updated
Apr 13, 2026
official title
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol